Innovaderm Bolsters European Presence With Two Newly-Established Operations Hubs (Spain & Poland)
Innovaderm announced today that its strategic European expansion initiative has reached a major milestone with the launch of two key centres of operations in Poland and Spain.
Biotechnology and pharmaceutical companies can officially partner with the CRO’s team of experts in Europe to manage clinical trials in psoriasis, acne, atopic dermatitis and other dermatology indications. This includes adherence to stringent regulatory requirements, patient recruitment, site selection, clinical monitoring and protocol writing.
“To date, we have successfully completed more than 500 clinical trials at 2,900 sites,” says Dave Selkirk, Innovaderm’s Chief Operating Officer. “The presence of two operations hubs in Europe will allow us to go one step further and accelerate the development of promising therapies that have the potential to transform lives. As we look to the future, our goal is to continue supporting innovation in research and the increasing number of patients with skin conditions worldwide.”
“These are exciting times for Innovaderm,” adds Anne Marie Gaulin, Chief Business Officer. “Our highly skilled employees are specialized in dermatology and understand the nuances of deep regional and pan-European requirements. With its site network, medical expertise, and established KOL relationships, Innovaderm’s team in Europe is ready to help customers advance the next generation of dermatology treatments.”
Innovaderm is one of the largest, independent, full-service CROs in the field of dermatology with early to late phase clinical trial capabilities in 30+ indications. For more information, visit our website.
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Innovaderm Research Inc.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Alliance on Green Economy launched during World Green Economy Summit in Dubai3.10.2022 09:00:00 CEST | Press release
Under the patronage of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the 8th World Green Economy Summit (WGES) concluded in Dubai. It was organised by the World Green Economy Organization (WGEO), Dubai Electricity and Water Authority (DEWA), and the Dubai Supreme Council of Energy. The summit was held under the theme ‘Climate Action Leadership through Collaboration: The Roadmap to Net-Zero’. A large number of ministers, experts, decision-makers, officials, representatives of institutions, and the academic community from around the world took part in the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221003005176/en/ Global Alliance on Green Economy launched during World Green Economy Summit in Dubai (Photo: AETOSWire) During a ministerial roundtable on green economy at WGES with around 25 ministers and officials from around the world, HE Saeed Mohammed Al T
Slate Asset Management Holds Third Close of Slate European Essential Real Estate Income Fund3.10.2022 09:00:00 CEST | Press release
Slate Asset Management ("Slate"), a global alternative investment platform targeting real assets, today announced that Slate European Essential Real Estate Income Fund (“SEEREIF” or the “Fund”) has reached its third close of the 2022 calendar year, significantly increasing the Fund’s available equity commitments for deployment. SEEREIF is backed by a diversified group of global institutional investors. The Fund is part of Slate’s core-plus investment strategy focused on European essential real estate, which targets cash yielding assets critical to the supply chain with high credit quality tenants, such as grocery and other essential consumer goods providers, healthcare assets, and affiliated warehouses and logistics centers. Jerry Cain, Managing Director of Investor Relations at Slate, said: “For the second quarter in a row, SEEREIF has closed on capital commitments from Slate’s global institutional partners, indicating that our investors recognize the uniquely resilient nature of this
Monument Re Announces Merger of AME Life Lux S.A. Into Monument Assurance Luxembourg S.A.3.10.2022 09:00:00 CEST | Press release
Monument Re announced today that AME Life Lux S.A. will merge into Monument Assurance Luxembourg S.A. following receipt of regulatory approval from the Commissariat aux Assurances. As a result, Monument Assurance Luxembourg S.A. will be the sole Monument Luxembourg entity following the merger. Monument Re Limited is a reinsurer and asset consolidator with a proven track record in the acquisition and operation of portfolios or direct insurers in Europe. Monument Re has a presence in Bermuda which has full Solvency II equivalence along with Switzerland. The Monument Re Group also operates through its subsidiaries in Belgium, Ireland, Isle of Man, Guernsey and Luxembourg, with branches in Spain, Italy and Germany. Each entity is subject to local regulation and Monument Re is subject to Group Supervision by the Bermuda Monetary Authority. Monument Assurance Luxembourg S.A. is a fully licensed Luxembourg life insurance company regulated by the Commissariat aux Assurances, with branches in S
Prodapt Launches OpenFibreXchange to Accelerate Pan-UK Digital Connectivity3.10.2022 08:00:00 CEST | Press release
Prodapt, a leading global consulting, technology, and managed services provider to the connectedness industry, today announced the launch of its OpenFibreXchange (OFX) that will enable Internet Service Providers (ISPs) to rapidly connect with the regional fibre operators to boost high-speed digital connectivity across the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220930005312/en/ With a singular focus on the Connectedness industry, Prodapt’s OpenFibreXchange, built on cloud-native, open-source technology, will enable wholesale fibre aggregation in the UK to accelerate digital Connectedness. ISPs can seamlessly connect with regional fibre operators via OFX to deliver pan-UK digital connectivity. Prodapt is committed to accelerating the digitisation of Britain and connecting hard-to-reach communities. The investment in OFX resulted from open discussions with delegates from retail & wholesale fibre AltNets, incumbent o
Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by GN Corporation3.10.2022 08:00:00 CEST | Press release
Treatment of cancer using one’s own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional chemotherapy, radiotherapy and surgery, practiced in Japan for long is now offered in Vinmec hospital, Hanoi, Vietnam, following technology transfer by GN Corporation. Cancer patients from neighboring countries are now visiting Vinmec hospital for this treatment. Autologous immune-cell therapy, regulated by the regenerative medicine law in Japan, uses lab-expanded autologous immune cells, without animal proteins or genetic manipulation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221002005087/en/ NK cells and T-cells in vitro culture method, without feeder cells or animal serum or genetic manipulation, for immune-cell therapy to cancer patients developed and practiced in Japan was tech-transferred to Vinmec Hospital, Hanoi, Vietnam, which was